AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27029851
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of azithromycin by mouth
Trial: 24285687
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg of anthocyanins twice daily for 24 weeks
Trial: 22966824
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy (scaling, root planing, and oral hygiene instructions)
Trial: 17145251
Drug: Long-term therapeutic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapeutic tinzaparin subcutaneously once daily for 3 months
Trial: 17145251
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care long-term vitamin-K-antagonist therapy for 3 months
Trial: 17145251
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care long-term vitamin-K-antagonist therapy
Trial: 14687502
Drug: 250 U/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 U/0.5 ml/dose of Healive vaccine
Trial: 14687502
Drug: 500 U/1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 U/1.0 ml/dose of Healive vaccine
Trial: 9013098
Drug: Parenteral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral oestrogen therapy (polyestradiol phosphate 240 mg i.m. every month)
Trial: 1327850
Drug: Oral slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral slow-release theophylline
Trial: 27570988
Drug: Intervention arm
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention arm with pharmacist review of chronic medication according to STOPP‐START criteria; recommendations sent to Primary Care Physician.
Trial: 18155216
Drug: 0.4% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% sodium hyaluronate solution
Trial: 15991510
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg hyperbaric ropivacaine + 10 microg fentanyl
Trial: 28619613
Drug: Supplemental photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental photodynamic therapy (PDT) in one-visit treatment
Trial: 28619613
Drug: Supplemental photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental photodynamic therapy (PDT) in two-visit treatment
Trial: 28619613
Drug: Chemo-mechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-mechanical preparation (CMP) alone in two-visit treatment
Trial: 28619613
Drug: Supplemental photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental photodynamic therapy (PDT)
Trial: 22933048
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of olanzapine (10 mg)
Trial: 22933048
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of olanzapine (10 mg)
Trial: 15809124
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GA and EA (CA)
Trial: 12136612
Drug: K+ channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K+ channel blockers
Trial: 12136612
Drug: Traditional anti‐arrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional anti‐arrhythmic drugs
Trial: 12136612
Drug: Anti‐arrhythmic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐arrhythmic drug selection
Trial: 12136612
Drug: Anti‐arrhythmic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐arrhythmic treatment
Trial: 10440638
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg metronidazole administered at 8-hour intervals for 1 week
Trial: 10440638
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 8-hour intervals for 1 week
Trial: 10440638
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg metronidazole
Trial: 7767709
Drug: Periodontal hygienic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periodontal hygienic treatment (n = 11 after treatment)
Trial: 7767709
Drug: Before treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before treatment (n = 9)
Trial: 2181860
Drug: 40 mmol
RxNorm normalized name: citrate 18 mmol / sodium 140 mmol in L Injection (EUA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mmol Mg aspartate (20 mmol elemental Mg twice daily)
Trial: 26366886
Drug: Computer-assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive behavioral therapy (CBT)
Trial: 17182183
Drug: Morphine (15-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (15-90 mg)
Trial: 17182183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and nortriptyline
Trial: 17182183
Drug: Benztropine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine (active placebo, 0.25-1 mg)
Trial: 15539665
Drug: Colombian antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colombian antivenom (20 ml initial dose)
Trial: 15539665
Drug: Colombian antivenom
RxNorm normalized name: ANTIVENIN,CROTALIDAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colombian antivenom (< 70 ml initial dose)
Trial: 11185630
Drug: telmisartan 160
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 160 mg
Trial: 11185630
Drug: telmisartan 160
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: telmisartan 160 mg plus hydrochlorothiazide 25 mg
Trial: 9103344
Drug: Generic levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic levothyroxine sodium preparations
Trial: 9103344
Drug: All products
RxNorm normalized name: All Clear Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All products (Synthroid, Levoxine, and 2 generic preparations)
Trial: 1503098
Drug: Interferon-alpha (IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN alpha) at a dose of 3 megaunits three times a week intramuscularly for 1 year
Trial: 6094423
Drug: Ro 09‐0415,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 09‐0415, 1200 mg bd orally before and after challenge with rhinovirus type 9
Trial: 25559798
Drug: Linifanib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib 7.5 mg (arm B)
Trial: 25559798
Drug: Linifanib 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib 12.5 mg (arm C)
Trial: 10536556
Drug: Org 9487
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 9487 (1.5 mg kg‐1 initial dose followed by three repeat doses or a 30‐min infusion)
Trial: 10536556
Drug: Rocuronium (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (two incremental doses)
Trial: 10536556
Drug: Neostigmine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine administration after Org 9487
Trial: 367024
Drug: Diluted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted heparin 5 000 IU/ml
Trial: 367024
Drug: Concentrated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated heparin 25 000 IU/ml
Trial: 31702876
Drug: Trivalent live
RxNorm normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent live attenuated influenza vaccine (TLAIV)
Trial: 19821984
Drug: Internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-help problem-solving therapy
Trial: 15729083
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract (900 mg/day)
Trial: 12660503
Drug: Kidney recipients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney recipients receiving oral prednisone (20 patients)
Trial: 12660503
Drug: Liver recipients
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver recipients receiving oral prednisone (6 patients)
Trial: 580598
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Trial: 25266443
Drug: 5-fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5FU) and leucovorin (LV) as bolus injections (Mayo or modified Mayo) or bi-monthly with bolus and continuous infusion (LV5FU2 or simplified LV5FU2)
Trial: 18762597
Drug: Pictogram-based medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pictogram-based medication instruction sheets
Trial: 12115793
Drug: Tumor bed
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor bed radiotherapy (TBRT) using interstitial high-dose-rate brachytherapy (HDR-BT) of 7 x 4.33 Gy (n = 8) and 7 x 5.2 Gy (n = 37)
Trial: 9935117
Drug: Culture medium
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture medium with FBS supplemented with physiologic (75 mIU/mL) FSH
Trial: 9935117
Drug: Culture medium
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture medium with FBS supplemented with supraphysiologic (7,500 mIU/mL) FSH
Trial: 8688926
Drug: Normative Treatment
RxNorm normalized name: K Norm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normative Treatment Planning (NTP)
Trial: 30997657
Drug: Orafil-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orafil-G
Trial: 26039212
Drug: T cell-depleted
RxNorm normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T cell-depleted haploidentical transplantation followed by infusion of genetically modified donor T cells (TK007 study)
Trial: 26039212
Drug: Sirolimus-based, calcineurin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD with unmanipulated PBSCs from haploidentical family donors (TrRaMM study)
Trial: 22915288
Drug: LB03002 (sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 (sustained-release recombinant human GH)
Trial: 19812228
Drug: TNFi+MTX (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi+MTX (TNF inhibitors combined with Methotrexate)
Trial: 14633531
Drug: Preoperative interscalene
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative interscalene block with 30 mL of 0.5% levobupivacaine
Trial: 14633531
Drug: Postoperative interscalene
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative interscalene block with 30 mL of 0.5% levobupivacaine
Trial: 10975586
Drug: TAK-044 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-044 (25, 50, or 100 mg, i.v.)
Trial: 9394260
Drug: Therapy programs
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy programs for depression
Trial: 3158620
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied 2% zinc sulfate solution
Trial: 24302681
Drug: DHEA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (400 mg)
Trial: 23161039
Drug: Scheduled time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled time administration of Ketorolac (bolus after surgical incision and then every 8 hours for 24 hours)
Trial: 23161039
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Ketorolac (2 ml/h for 24 hours)
Trial: 20832963
Drug: Ticagrelor (180‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180‐mg loading dose, 90 mg twice daily)
Trial: 20832963
Drug: Clopidogrel (300‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300‐ to 600‐mg loading dose, 75 mg/day)
Trial: 16015250
Drug: Beverage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage with 5 g beta-glucans from oats
Trial: 16015250
Drug: Beverage with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage with 10 g beta-glucans from oats
Trial: 11796602
Drug: Intranasal NOMV
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal NOMV vaccine
Trial: 11796602
Drug: Intranasal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal and oropharyngeal NOMV vaccine
Trial: 11796602
Drug: Group receiving
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group receiving extra vaccine dose
Trial: 10643695
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment with >50% improvement after 1 year
Trial: 10643695
Drug: Methotrexate treatment
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate treatment with 20-50% improvement after 1 year
Trial: 10643695
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who discontinued methotrexate treatment during the first year
Trial: 1380432
Drug: Tropisetron 10mg
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 10mg intravenously before and after cisplatin infusion
Trial: 1380432
Drug: Metoclopramide 2
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 2 mg/kg plus lorazepam administered 15 minutes before cisplatin
Trial: 6092288
Drug: Antacid 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid 60 ml/day
Trial: 30844687
Drug: Selenomethionine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenomethionine (200 μg daily)
Trial: 30844687
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (4000 IU daily)
Trial: 28911155
Drug: Interleukin‐1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin‐1 receptor antagonist (IL‐1RA)
Trial: 23326188
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid alone (66 mg)
Trial: 23326188
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (49.5 mg) plus diclofenac sodium (5 mg)
Trial: 23326188
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (49.5 mg) plus sodium clodronate (5 mg)
Trial: 17614029
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of prednisolone (Pred)
Trial: 3087801
Drug: Terfenadine (TRF)
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine (TRF) 60 mg b.i.d. for 7 days
Trial: 3087801
Drug: Mequitazine (MQZ)
RxNorm normalized name: mequitazine
DrugBank: Mequitazine (DB01071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mequitazine (MQZ) 5 mg b.i.d. for 7 days
Trial: 2819021
Drug: Ca-enriched milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca-enriched milk (1 pint daily for 4 weeks)
Trial: 23458591
Drug: LCI699 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (0.25 mg twice daily, 1 mg four times daily, and 0.5 mg/1 mg twice daily)
Trial: 23458591
Drug: Eplerenone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (50 mg twice daily)
Trial: 20579848
Drug: High dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dairy (∼ 1300 mg/d of calcium from dairy products)
Trial: 20579848
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium (∼ 1300 mg/d of calcium; ∼ 700 mg/d from diet and 600 mg/d from a supplement)
Trial: 16503524
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine intravenous oxytocin infusion)
Trial: 15055095
Drug: Modified Hatha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Hatha yoga intervention (1 hour, twice a week for 6 weeks)
Trial: 15055095
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during observation period)
Trial: 23681501
Drug: Gadobutrol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobutrol (all doses)
Trial: 20133200
Drug: rFSH only
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rFSH only with GnRH antagonist
Trial: 18226768
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy plus cardiac resynchronization therapy (CRT)
Trial: 18226768
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (OPT)
Trial: 16427528
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine IV before surgical incision, followed by normal saline infusion and normal saline IV at wound closure (Group 1)
Trial: 16427528
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine IV before surgery, followed by ketamine infusion 600 mug . kg(‐1) . h(‐1) until wound closure (Group 2)
Trial: 16427528
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV before surgery, followed by saline infusion and then 0.5 mg/kg ketamine IV at wound closure (Group 3)
Trial: 8307847
Drug: Propranolol (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.2 mg/kg iv)
Trial: 8307847
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg/kg iv)
Trial: 31100535
Drug: iGlebe (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlebe (internet-based cognitive behavior therapy) for 5 months
Trial: 24907137
Drug: Pediatric aquatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric aquatic therapy
Trial: 22887778
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 35% comfrey root extract plus 1.2% methyl nicotinate
Trial: 20102347
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (1.25 mg) injection
Trial: 19248200
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg once daily for 8 weeks)
Trial: 19248200
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily for 8 weeks)
Trial: 19248200
Drug: Pantoprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (40 mg once daily for 8 weeks)
Trial: 17602058
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens including thalidomide
Trial: 17602058
Drug: Bortezomib, thalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib, thalidomide, lenalidomide, and other novel agents
Trial: 25595138
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/day) + inhaled beclometasone (400 μg/day)
Trial: 25595138
Drug: Inhaled beclometasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclometasone (400 μg/day)
Trial: 25595138
Drug: Atorvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin + inhaled beclometasone
Trial: 21828967
Drug: 2% mupirocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mupirocin ointment applied to the nares twice daily
Trial: 21828967
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin plus daily 4% chlorhexidine body washes
Trial: 21828967
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin plus daily dilute bleach water baths